Abstract
Antibodies to merozoite surface antigens (MSPs), the primary targets of malaria vaccine research, are associated with low malaria morbidity. However, few studies have looked at the implications of their variations on the evolution of clinical-biological forms of severe malaria.
Highlights
IntroductionThe World Health Organization (WHO) estimates that 3.3 billion people are at risk of infection with an incidence of 229 million cases associated with 409,000 deaths per year [1]
Plasmodium falciparum malaria remains a global public health problem
Anti-MSP1, MSP4-20, and MSP4 antibodies are involved in the anti-plasmodial humoral response in severe malaria
Summary
The World Health Organization (WHO) estimates that 3.3 billion people are at risk of infection with an incidence of 229 million cases associated with 409,000 deaths per year [1]. In Senegal, between 2018 and 2019, the incidence of malaria decreased by 35.4% [6] This decrease in endemicity exposes to severe forms [2,7]. Adequate management of these severe forms implies a better understanding of their pathophysiology in which the involvement of antibodies has been widely demonstrated [8,9,10]. Several Senegalese studies have confirmed the significant relationship between high levels of anti-MSP1, MSP4-20, MSP4-40 antibodies (Ac) and low malaria morbidity and mortality [11,12,13]. Few studies have looked at the implications of their variations on the evolution of clinical-biological forms of severe malaria
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
